Abstract
Most patients with pancreatic ductal adenocarcinoma (PDAC) present with unresectable or metastatic disease. Standard first line chemotherapy is with gemcitabine and nab-paclitaxel, or FOLFIRINOX and median overall survival (OS) remains poor, under 12 months. The dense PDAC stroma acts as a barrier to drug delivery. CEND-1 is a novel cyclic tumor-penetrating peptide iRGD (internalizing arginylglycylaspartic acid) that may improve drug delivery by activating an endocytic/exocytic transport pathway by binding αvB3/5-integrins and downstream neuropilin-1.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
